🇺🇸 FDA
Patent

US 10023650

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

granted A61KA61K2039/505A61K39/39558

Quick answer

US patent 10023650 (Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers) held by PRECISION BIOLOGICS, INC. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PRECISION BIOLOGICS, INC.
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K39/39558, A61K45/06, A61K47/6859